Anna Maria Langkilde

Also affiliated with AstraZeneca (Finland), AstraZeneca (Sweden), AstraZeneca (Spain)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 30 papers. Top paper: “Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes”.

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

JAMA(2020)10.1001/jama.2020.1906

N/A

6.7DataRank · unranked

539 citations

Subodh Verma, Kieran F. Docherty, Silvio E. Inzucchi, Inder S. Anand, Jan Bělohlávek +34 more

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan

JACC Heart Failure(2020)10.1016/j.jchf.2020.04.008

N/A

5.0DataRank · unranked

142 citations

Pardeep S. Jhund, Brian Claggett, Pooja Dewan, Lars Køber, Mikhail Kosiborod +11 more

Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF

Circulation(2022)10.1161/circulationaha.121.058910

N/A

4.7DataRank · unranked

131 citations

Kieran F. Docherty, Hiddo J.L. Heerspink, Rudolf A. de Boer, Kevin Damman, Silvio E. Inzucchi +16 more

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial

Circulation(2022)10.1161/circulationaha.122.061754

N/A

4.2DataRank · unranked

152 citations

Pardeep S. Jhund, Jan Bělohlávek, Rudolf A. de Boer, Chern‐En Chiang, Akshay S. Desai +22 more

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JAMA Cardiology(2022)10.1001/jamacardio.2022.3750

N/A

2.9DataRank · unranked

67 citations

Brian Claggett, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi +12 more

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

Diabetes Care(2020)10.2337/dc20-1675

N/A

2.7DataRank · unranked

76 citations

Kieran F. Docherty, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr Ponikowski +16 more

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Nature Medicine(2022)10.1038/s41591-022-02102-9

N/A

1.7DataRank · unranked

67 citations

James C. Fang, Akshay S. Desai, Pardeep S. Jhund, Brian Claggett, Muthiah Vaduganathan +19 more

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF

European Journal of Heart Failure(2020)10.1002/ejhf.2083

N/A

1.7DataRank · unranked

48 citations

Kieran F. Docherty, Olof Bengtsson, Rudolf A. de Boer, Akshay S. Desai, Jarosław Dróżdż +19 more

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

European Heart Journal(2023)10.1093/eurheartj/ehad283

N/A

1.6DataRank · unranked

56 citations

Muthiah Vaduganathan, Brian Claggett, Orly Vardeny, Akshay S. Desai, Pardeep S. Jhund +15 more

Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER

Circulation(2022)10.1161/circulationaha.122.062832

N/A

1.5DataRank · unranked

56 citations

Muthiah Vaduganathan, Brian Claggett, Sheila M. Hegde, Maria Pabón, Ian J. Kulac +22 more

Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JACC Heart Failure(2022)10.1016/j.jchf.2022.08.007

N/A

1.5DataRank · unranked

50 citations

Muthiah Vaduganathan, Brian Claggett, Zi Michael Miao, Pardeep S. Jhund, Rudolf A. de Boer +13 more

Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score

JACC Heart Failure(2022)10.1016/j.jchf.2022.03.009

N/A

1.4DataRank · unranked

29 citations

Pooja Dewan, Ersilia M. DeFilippis, Tor Biering‐Sørensen, Kieran F. Docherty, Pardeep S. Jhund +13 more

Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial

Circulation(2023)10.1161/circulationaha.123.066506

N/A

1.3DataRank · unranked

36 citations

Muthiah Vaduganathan, Brian Claggett, Jonathan W. Cunningham, Kieran F. Docherty, Akshay S. Desai +13 more

Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial

The Lancet Diabetes & Endocrinology(2022)10.1016/s2213-8587(22)00308-4

N/A

1.2DataRank · unranked

41 citations

Brian Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer +14 more

Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure

Circulation Heart Failure(2020)10.1161/circheartfailure.120.007879

N/A

1.1DataRank · unranked

27 citations

Pooja Dewan, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod +9 more

Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JAMA Cardiology(2023)10.1001/jamacardio.2023.4664

N/A

1.0DataRank · unranked

38 citations

Brian Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Orly Vardeny +17 more

Effect of Dapagliflozin on Health Status and Quality of Life Across the Spectrum of Ejection Fraction: Participant-Level Pooled Analysis from the DAPA-HF and DELIVER Trials

European Journal of Heart Failure(2023)10.1002/ejhf.2909

N/A

1.0DataRank · unranked

22 citations

Mikhail Kosiborod, Muthiah Vaduganathan, Brian Claggett, Zi Michael Miao, Ian J. Kulac +13 more

Relationship of Dapagliflozin With Serum Sodium

JACC Heart Failure(2022)10.1016/j.jchf.2022.01.019

N/A

0.999DataRank · unranked

31 citations

Kieran F. Docherty, Pardeep S. Jhund, Mark C. Petrie, Silvio E. Inzucchi, Lars Køber +12 more

Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

JACC Heart Failure(2021)10.1016/j.jchf.2021.08.006

N/A

0.900DataRank · unranked

49 citations

Modele O. Ogunniyi, Inder S. Anand, Akshay S. Desai, Mirta Díez, Jonathan G. Howlett +17 more

Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Circulation(2023)10.1161/circulationaha.123.065254

N/A

0.805DataRank · unranked

21 citations

Muthiah Vaduganathan, Senthil Selvaraj, Brian Claggett, Zi Michael Miao, Akshay S. Desai +13 more

Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial

European Journal of Heart Failure(2023)10.1002/ejhf.3043

N/A

0.691DataRank · unranked

16 citations

Mikhail Kosiborod, Brian Claggett, Zi Michael Miao, Muthiah Vaduganathan, Carolyn S.P. Lam +19 more

Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JAMA Cardiology(2023)10.1001/jamacardio.2023.1342

N/A

0.671DataRank · unranked

13 citations

Alvin Chandra, Mikhail Kosiborod, Brian Claggett, Akshay S. Desai, Pardeep S. Jhund +17 more

Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF

JACC Heart Failure(2022)10.1016/j.jchf.2021.09.002

N/A

0.614DataRank · unranked

13 citations

Joanne Simpson, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod +10 more

Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial

Circulation(2023)10.1161/circulationaha.122.062918

N/A

0.405DataRank · unranked

7 citations

Karola Jering, C. Jan Willem Borleffs, Rudolf A. de Boer, Brian Claggett, Akshay S. Desai +15 more

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial

Cardiovascular Diabetology(2025)10.1186/s12933-025-02875-6

N/A

0DataRank · unranked

0 citations

Remo H.M. Furtado, Russell Esterline, Jan Oscarsson, Samvel B. Gasparyan, Gary G. Koch +18 more

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure

Journal of Cardiac Failure(2021)10.1016/j.cardfail.2021.07.003

N/A

0DataRank · unranked

31 citations

Peter J. Greasley, David C. Wheeler, Glenn M. Chertow, Anna Maria Langkilde, Hiddo J.L. Heerspink +2 more

Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan

European Journal of Heart Failure(2022)10.1002/ejhf.2722

N/A

0DataRank · unranked

34 citations

Jawad H. Butt, Toru Kondo, Karola Jering, Kieran F. Docherty, Pardeep S. Jhund +16 more

Dapagliflozin in Patients with Heart Failure and Previous Myocardial Infarction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER

European Journal of Heart Failure(2024)10.1002/ejhf.3184

N/A

0DataRank · unranked

11 citations

Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Alberto Foà, Akshay S. Desai +17 more

Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease

European Heart Journal(2024)10.1093/eurheartj/ehae780

N/A

0DataRank · unranked

8 citations

Mats Christian Højbjerg Lassen, Brian Claggett, Zi Michael Miao, Silvio E. Inzucchi, Kieran F. Docherty +16 more

POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR <30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL

Kidney International Reports(2021)10.1016/j.ekir.2021.03.869

N/A

0DataRank · unranked

3 citations

Priya Vart, Niels Jongs, Robert D. Toto, José Luis Górriz, Fan Fan Hou +9 more